journal
Journals Breast Cancer : Targets and Th...

Breast Cancer : Targets and Therapy

https://read.qxmd.com/read/38020051/efficacy-and-safety-of-radiotherapy-combined-with-pyrotinib-in-the-treatment-of-her2-positive-breast-cancer-with-brain-metastases
#21
JOURNAL ARTICLE
Jie Huang, Wenqiang Zhu, Qiangzhi Duan, Chaomang Zhu, Xueling Shi, Hongyu Zhao, Peng Cai, Duojie Li
PURPOSE: To explore the efficacy and safety of pyrotinib combined with different radiotherapy modes in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC) patients with brain metastasis (BM). PATIENTS AND METHODS: This study is a retrospective analysis of patients diagnosed with BM who underwent treatment with pyrotinib between November 2018 and April 2023. A total of 66 patients were administered radiotherapy in conjunction with pyrotinib (Group A), while 26 patients received pyrotinib as a standalone treatment (Group B)...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/38020050/psychometric-properties-and-factorial-analysis-of-the-arabic-mcgill-qol-questionnaire-in-breast-cancer
#22
JOURNAL ARTICLE
Mohammed T A Omar, Ali H Alnahdi
PURPOSE: This study aimed to assess the psychometric properties of the Arabic McGill Quality of Life Questionnaire-Revised (MQOL-R) in breast cancer survivors. PATIENTS AND METHODS: One-hundred-forty breast cancer survivors were recruited and completed the questionnaire. The construct validity was assessed using confirmatory factor analysis (CFA). MQOL-R scores were correlated with Global Health Status/QoL and functional subscales of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) for convergent validity...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/38020049/early-real-world-treatment-patterns-and-clinical-outcomes-in-patients-with-metastatic-breast-cancer-treated-with-eribulin-after-prior-immuno-oncology-or-antibody-drug-conjugate-therapy
#23
JOURNAL ARTICLE
Ravi K Goyal, Jingchuan Zhang, Keith L Davis, Martina Sluga-O'Callaghan, Peter A Kaufman
INTRODUCTION: Eribulin was approved by the FDA in 2010 for the treatment of metastatic breast cancer (MBC) in the United States (US). More recently, several immuno-oncology (IO) and antibody-drug conjugate (ADC) regimens have been approved for MBC. We assessed the treatment patterns and clinical outcomes in MBC patients treated with eribulin following treatment with an IO or ADC in US clinical practice. MATERIALS AND METHODS: In a retrospective patient medical chart review study, patients with MBC, aged ≥18 years, who initiated eribulin therapy between March 1, 2019, and September 30, 2020, treated with either prior IO or ADC in the metastatic setting were included...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/38020048/abcb1-regulates-immune-genes-in-breast-cancer
#24
JOURNAL ARTICLE
Han-Kun Chen, Yi-Ling Chen, Chih-Yang Wang, Wei-Pang Chung, Jung-Hua Fang, Ming-Derg Lai, Hui-Ping Hsu
BACKGROUND: Resistance to standard chemotherapy is a critical problem for breast cancer patients. The ATP-binding cassette (ABC) superfamily transporters actively pump out drugs and play an important role in chemoresistance. ABCB1 (ABC subfamily B, member 1, also named as multidrug resistance protein 1, MDR1) and suppressive myeloid-derived suppressor cells (MDSCs) potentially involve in chemoresistance of breast cancer. The relationship between ABCB1 and immune genes in breast cancer has not been widely studied...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37954171/therapeutic-advantage-of-targeting-prmt5-in-combination-with-chemotherapies-or-egfr-her2-inhibitors-in-triple-negative-breast-cancers
#25
JOURNAL ARTICLE
Rayan Dakroub, Solène Huard, Yara Hajj-Younes, Samyuktha Suresh, Bassam Badran, Hussein Fayyad-Kazan, Thierry Dubois
PURPOSE: Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subgroup characterized by a high risk of resistance to chemotherapies and high relapse potential. TNBC shows inter-and intra-tumoral heterogeneity; more than half expresses high EGFR levels and about 30% are classified as HER2-low breast cancers. High PRMT5 mRNA levels are associated with poor prognosis in TNBC and inhibiting PRMT5 impairs the viability of subsets of TNBC cell lines and delays tumor growth in TNBC mice models...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37936879/advances-in-tumour-infiltrating-lymphocytes-for-triple-negative-breast-cancer-management
#26
REVIEW
Rok Gorenšek, Martin Kresnik, Iztok Takač, Tomaž Rojko, Monika Sobočan
Triple negative breast cancer (TNBC) is a subtype of breast cancer which does not express or expresses a minimum amount of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) protein. TNBCs include a heterogenic group of cancers that are aggressive, grow rapidly and are associated with poor prognosis and overall survival, mainly attributed to a lack of effective therapeutic targets. For a long time, a major issue with predicting the outcome and prognosis of TNBCs was the lack of an accurate biomarker, a molecule that helps us objectively assess a patient's health status...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37927491/a-review-on-the-management-of-peripheral-neuropathic-pain-following-breast-cancer
#27
REVIEW
Francisco Avila, Ricardo Torres-Guzman, Karla Maita, John P Garcia, Gioacchino D De Sario, Sahar Borna, Olivia A Ho, Antonio J Forte
Postmastectomy pain syndrome (PMPS) is a common and debilitating form of postsurgical pain with neuropathic characteristics, presenting as burning, stabbing, or pulling sensations after mastectomy, lumpectomy, or other breast procedures. With a prevalence of 31%, the risk factors for PMPS include younger age, psychosocial factors, radiotherapy, axillary lymph node dissection, and a history of chronic pain. This review evaluates the pharmacological and surgical options for managing PMPS. Pharmacological treatment options include antidepressants, gabapentinoids, levetiracetam, capsaicin, and topical lidocaine...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37915543/traditional-chinese-medicine-for-breast-cancer-a-review
#28
REVIEW
Rui-Qi Feng, De-Hui Li, Xu-Kuo Liu, Xiao-Hui Zhao, Qian-Er Wen, Ying Yang
A total of 18% of global breast cancer (BC) deaths are attributed to BC in China, making it one of the five most common cancers there. There has been a steady rise in BC morbidity and mortality in women in the last few years and it is now a leading cancer among Chinese women. Conventional treatments for BC are currently effective but have several limitations and disadvantages, and Traditional Chinese medicine (TCM) plays a vital role in the overall process of cancer prevention and therapy. It is known that TCM can treat a variety of conditions at a variety of sites and targets...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37905205/pdl1-based-nomogram-may-be-of-potential-clinical-utility-for-predicting-survival-outcome-in-stage-iii-breast-cancer
#29
JOURNAL ARTICLE
Xi Zhang, Ruzhe Li, Guonian Wang
PURPOSE: Programmed cell death ligand 1 (PDL1) has the predictive and prognostic value in a great deal of cancers. This study aims to explore the expression of PDL1 in stage III breast cancer (BC) and its correlation with clinical outcome. METHODS: The protein expression of PDL1 in tumor tissues was determined by immunohistochemistry (IHC). The correlations between PDL1 and clinicopathological variables were performed by χ² -tests or Fisher's exact tests...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37881514/breast-cancer-an-overview-of-current-therapeutic-strategies-challenge-and-perspectives
#30
REVIEW
Jun Wang, San-Gang Wu
Breast cancer is the most commonly diagnosed cancer and the leading cause of death among female patients, which seriously threatens the health of women in the whole world. The treatments of breast cancer require the cooperation of a multidisciplinary setting and taking tumor load and molecular makers into account. For early breast cancer, breast-conserving surgery with radiotherapy or mastectomy alone remains the standard management, and the administration of adjuvant systemic therapy is decided by the status of lymph nodes, hormone receptors, and human epidermal growth factor receptor-2...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37873521/a-comprehensive-model-based-on-dynamic-contrast-enhanced-magnetic-resonance-imaging-can-better-predict-the-preoperative-histological-grade-of-breast-cancer-than-a-radiomics-model
#31
JOURNAL ARTICLE
Yitian Wu, Weixing Pan, Lingxia Wang, Wenting Pan, Huangqi Zhang, Shengze Jin, Xiuli Wu, Aie Liu, Enhui Xin, Wenbin Ji
BACKGROUND: Histological grade is an important prognostic factor for patients with breast cancer and can affect clinical decision-making. From a clinical perspective, developing an efficient and non-invasive method for evaluating histological grading is desirable, facilitating improved clinical decision-making by physicians. This study aimed to develop an integrated model based on radiomics and clinical imaging features for preoperative prediction of histological grade invasive breast cancer...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37873520/hsa_circ_0007823-overexpression-suppresses-the-progression-of-triple-negative-breast-cancer-via-regulating-mir-182-5p-foxo1-axis
#32
JOURNAL ARTICLE
Jinling Yu, Haofeng Wang, Weida Shen, Yingzi Zhou, Jing Cui, Haichuan Li, Beimin Gao
BACKGROUND: This study aimed to analyze the specific expression of hsa_circ_0007823 in triple-negative breast cancer (TNBC) and explore the roles and related molecular mechanisms of hsa_circ_0007823 in TNBC. MATERIALS AND METHODS: Relative hsa_circ_0007823 levels in TNBC tissues and cell lines were examined by reverse transcription-quantitative polymerase chain reaction. The value of hsa_circ_0007823 levels was evaluated in patients' clinicopathological characteristics and prognostic prediction...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37850030/the-impact-of-deep-inspiration-breath-hold-dibh-implementation-on-the-hybrid-technique-in-left-sided-whole-breast-irradiation-a-dosimetric-characteristic-study-of-3d-crt-hybrid-vmat-in-dibh-and-free-breathing-conditions-and-vmat-in-free-breathing-conditions
#33
JOURNAL ARTICLE
Hui-Ling Yeh, Jia-Fu Lin
AIM: To investigate the impact of DIBH for heart sparing effect on left sided breast postoperative whole breast irradiation by comparing the dosimetric characteristics of 3D-CRT hybrid VMAT and pure VMAT treatment planning under DIBH condition. MATERIALS AND METHODS: The primary CT data sets from previously treated left sided early breast cancer were used for pure volumetric arc therapy (VMAT) technique re-planning for the dosimetric characteristics comparison. A treatment plan of 3D-CRT hybrid VMAT technique was re-planned on the free breath (FB) condition for the investigation of the dosimetric characteristics comparison on DIBH condition...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37692097/survival-outcomes-and-efficacy-of-platinum-in-early-breast-cancer-patients-with-germline-brca1-or-brca2-mutation-a-multicenter-retrospective-cohort-study
#34
JOURNAL ARTICLE
Xi Chen, Xiaoyan Qian, Min Xiao, Pin Zhang
PURPOSE: The study aimed to compare the survival outcomes and efficacy of platinum in early breast cancer patients with BRCA1 and BRCA2 mutations. METHODS: Patients diagnosed with stage I-III breast cancer and carrying germline pathogenic/likely pathogenic BRCA mutations in three medical institutions in China from April 2016 to January 2021 were retrospectively analyzed. Data on clinical and pathological characteristics, treatment information, pathogenic variants of BRCA, and survival outcomes were collected for all eligible patients...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37674872/mcm-2-levels-as-a-potential-biomarker-for-predicting-high-risk-breast-cancer-patients-according-to-tailorx-classification
#35
JOURNAL ARTICLE
Çağlar Ünal, Tolga Özmen, Ahmet Serkan İlgün, Çetin Ordu, Enver Özkurt, Naziye Ak, Gül Alço, Zeynep Erdoğan İyigün, Sevgi Kurt, Tomris Duymaz, Mehmet Alper Öztürk, Filiz Elbüken Çelebi, Kanay Yararbaş, Gürsel Soybir, Fatma Aktepe, Vahit Özmen
BACKGROUND: The minichromosome maintenance protein-2 (MCM-2) is a more sensitive proliferation marker than Ki-67. This study aimed to evaluate the relationship between MCM-2 and Oncotype DX recurrence score (ODX-RS) and determine an MCM-2 cutoff value in high-risk patients according to TAILORx risk categorization. METHODS: Hormone receptor (HR) positive HER-2 negative early-stage breast cancer patients (pT1-2, pN0-N1, M0) who had ODX-RS were included in the study...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37644916/research-progress-on-molecular-subtyping-and-modern-treatment-of-triple-negative-breast-cancer
#36
REVIEW
Ling Tong, Xiangling Yu, Shan Wang, Ling Chen, Yibo Wu
Breast cancer has become the most common malignant tumor worldwide. Triple-negative breast cancer (TNBC) is a type of breast cancer that is negative for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Compared with other molecular subtypes of breast cancer, TNBC is the most aggressive and highly heterogeneous. TNBC is insensitive to endocrine and anti-HER2 therapy, and chemotherapy is currently the main systemic treatment. With the continuous development of detection techniques and deepening research on TNBC molecular subtypes, drugs targeting immune checkpoints and different targets have emerged, such as atezolizumab, pembrolizumab, poly (ADP-ribose) polymerase (PARP) inhibitors, trophoblast cell-surface antigen 2 (TROP-2), and antibody-drug conjugates...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37605715/risk-of-subsequent-breast-cancer-in-women-with-early-stage-her2-positive-breast-cancer-in-a-large-community-health-plan
#37
JOURNAL ARTICLE
Reina Haque, Lie Hong Chen, Nina Oestreicher, Deepa Lalla, Rowan T Chlebowski
PURPOSE: Clinical outcomes have improved for women with early stage, HER2-positive breast cancer following the FDA approval of adjuvant trastuzumab use in 2006. However, only limited information exists on such patients' outcomes in real-world settings outside of clinical trials. We examined the risk of subsequent breast cancer in women with HER-2 positive disease, and the impact of trastuzumab use, in a large California community-based health plan. PATIENTS AND METHODS: A cohort of 3550 women with HER2-positive breast cancer (stages I-III) from 2009-2017 were followed through December 2018...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37600671/diagnostic-value-of-a-combined-serum-%C3%AE-hydroxybutyrate-dehydrogenase-carcinoembryonic-antigen-and-glycoantigen-125-test-for-early-stage-breast-cancer
#38
JOURNAL ARTICLE
Chuan-Hua Zhan, Guo-Jun Liu
OBJECTIVE: To investigate the diagnostic value of the combined detection of α-hydroxybutyrate dehydrogenase (α-HBDH), carcinoembryonic antigen (CEA) and cancer antigen 125 (CA125) in early-stage breast cancer (ESBC). METHODS: This was a retrospective analysis of 169 patients with ESBC, 138 patients with benign breast disease (BBD) and 200 normal healthy controls (NHCs). The levels of serum α-HBDH, CEA and CA125 in the two groups were detected. The receiver operating characteristic (ROC) curve and area under the curve (AUC) were used to analyse the diagnostic value of the above indicators alone and in combination for ESBC...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37600670/her2-low-breast-cancer-current-landscape-and-future-prospects
#39
REVIEW
Yelena Shirman, Shlomit Lubovsky, Ayelet Shai
More than 50% of breast cancers are currently defined as "Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC)", with HER2 immunohistochemistry (IHC) scores of +1 or +2 with a negative fluorescence in situ hybridization (FISH) test. In most studies that compared the clinical and biological characteristics of HER2-low BC with HER2-negative BC, HER2-low was not associated with unique clinical and molecular characteristics, and it seems that the importance of HER2 in these tumors is being a docking site for the antibody portion of antibody drug conjugates (ADCs)...
2023: Breast Cancer: Targets and Therapy
https://read.qxmd.com/read/37600669/abvs-based-radiomics-for-early-predicting-the-efficacy-of-neoadjuvant-chemotherapy-in-patients-with-breast-cancers
#40
JOURNAL ARTICLE
Wei Jiang, Xiaofei Deng, Ting Zhu, Jing Fang, Jinyao Li
BACKGROUND: Neoadjuvant chemotherapy (NAC) plays a significant role in breast cancer (BC) management; however, its efficacy varies among patients. Current evaluation methods may lead to delayed treatment alterations, and traditional imaging modalities often yield inaccurate results. Radiomics, an emerging field in medical imaging, offers potential for improved tumor characterization and personalized medicine. Nevertheless, its application in early and accurately predicting NAC response remains underinvestigated...
2023: Breast Cancer: Targets and Therapy
journal
journal
47837
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.